Production (Stage)
Trevi Therapeutics, Inc.
TRVI
$6.29
$0.264.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.71M | 12.15M | 11.65M | 11.51M | 10.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.09M | 51.53M | 48.22M | 43.17M | 38.27M |
| Operating Income | -51.09M | -51.53M | -48.22M | -43.17M | -38.27M |
| Income Before Tax | -47.38M | -47.94M | -44.35M | -38.78M | -33.60M |
| Income Tax Expenses | -34.00K | -31.00K | -29.00K | -11.00K | -33.00K |
| Earnings from Continuing Operations | -47.35 | -47.91 | -44.32 | -38.77 | -33.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.35M | -47.91M | -44.32M | -38.77M | -33.57M |
| EBIT | -51.09M | -51.53M | -48.22M | -43.17M | -38.27M |
| EBITDA | -50.94M | -51.38M | -48.07M | -43.03M | -38.13M |
| EPS Basic | -0.45 | -0.47 | -0.44 | -0.39 | -0.34 |
| Normalized Basic EPS | -0.28 | -0.29 | -0.28 | -0.24 | -0.21 |
| EPS Diluted | -0.45 | -0.47 | -0.44 | -0.39 | -0.34 |
| Normalized Diluted EPS | -0.28 | -0.29 | -0.28 | -0.24 | -0.21 |
| Average Basic Shares Outstanding | 425.94M | 407.85M | 401.33M | 399.37M | 397.03M |
| Average Diluted Shares Outstanding | 425.94M | 407.85M | 401.33M | 399.37M | 397.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |